statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit,' 'we,' or the 'Company') today reports its financial results and provides an update on its operational progress for the first quarter ended March 31...

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. We are excited to...

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually...

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief...

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Investors eyeing a purchase of Summit Therapeutics Inc (SMMT) stock, but cautious about paying the going market price of 3.87/share, might benefit from considering selling puts among the...

Commit To Buy Summit Therapeutics At $3, Earn 24.6% Annualized Using Options

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks. However, Warren Buffett was not the only one making notable insider purchases in the past week or so. An NFL...

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) CEO Mahkam Zanganeh bought 30,000 shares of the business's stock in a transaction on Tuesday, March 26th. The shares were acquired at an...

Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Purchases $112,500.00 in Stock

One exceptional stock in the healthcare sector this trading week was Summit Therapeutics (NASDAQ: SMMT). Buoyed by encouraging news from the lab, the company got an additional boost on Monday with an...

Why Summit Therapeutics Stock Crushed the Market This Week

Ray Dalio Fears China Faces 'Lost Decade' - We Should Listen (Forbes)
Billionaire David Tepper Is Loading Up on These Artificial Intelligence (AI) Stocks - and Nvidia Isn't One of Them...

Hedge Fund and Insider Trading News: Cliff Asness, David Tepper, Ray Dalio, Mark Yusko, Baupost Group, Irenic Capital Management, Summit Therapeutics Inc (SMMT), Workday, Inc. (WDAY), and More

This is a signal that SMMT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Summit Therapeutics (SMMT, $4.12) Stochastic Oscillator left the oversold zone on March 28, 2024

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Volume	1.86M
52-Wk High	$5.22
52-Wk Low	$1.50

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.06	--	--	N/A
Q1'24	-$0.06	-$0.06	--	EXPECTED
Q1'23	--	-$1.43	--	N/A
Q4'22	--	-$0.07	--	N/A
Q3'22	--	-$0.14	--	N/A

SMMT Summit Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals